Skip to main content

Table 3 Power analysis and total sample size calculations assuming different changes in LVEF with alpha 0.05, power 0.8 and 0.9 and equal sized groups with a common standard deviation of 7.0%

From: Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial

Power 0.8

Power 0.9

Change in LVEF%

N

Change in LVEF%

N

Placebo

Sacubitril/-valsartan

delta

 

Placebo

Sacubitril/-valsartan

delta

 

2.6

0.7

1.9

430

2.6

0.7

1.9

574

2.6

1.4

1.2

1072

2.6

1.4

1.2

1434

3.4

0.7

2.7

214

3.4

0.7

2.7

286

3.4

1.4

2.0

388

3.4

1.4

2.0

518

4.2

0.7

3.5

128

4.2

0.7

3.5

172

4.2

1.4

2.8

200

4.2

1.4

2.8

266

  1. LVEF left ventricular ejection fraction